Edwards Lifesciences Financial Statements (EW)
|
|
Report date
|
|
|
12.02.2021 |
14.02.2022 |
31.12.2022 |
13.02.2023 |
12.02.2024 |
|
06.11.2024 |
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
4 386 |
5 233 |
5 382 |
5 382 |
6 005 |
|
5 724 |
Operating Income, bln rub |
|
|
1 628 |
1 349 |
1 749 |
1 749 |
1 534 |
|
1 574 |
EBITDA, bln rub |
? |
|
1 074 |
1 890 |
1 784 |
1 960 |
1 768 |
|
1 587 |
Net profit, bln rub |
? |
|
823.4 |
1 503 |
1 522 |
1 522 |
1 402 |
|
4 155 |
|
OCF, bln rub |
? |
|
1 054 |
1 732 |
|
1 218 |
895.8 |
|
1 041 |
CAPEX, bln rub |
? |
|
407.3 |
329.8 |
|
264.8 |
266.3 |
|
288.0 |
FCF, bln rub |
? |
|
647.0 |
1 402 |
|
953.4 |
629.5 |
|
753.3 |
Dividend payout, bln rub
|
|
|
0.000 |
0.000 |
|
0.000 |
0.000 |
|
0.000 |
|
Ordinary share dividend yield, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0.00% |
Dividend payout ratio, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0 |
|
OPEX, bln rub |
|
|
1 989 |
2 397 |
2 513 |
2 513 |
3 091 |
|
2 924 |
Cost of production, bln rub |
|
|
1 081 |
1 249 |
1 080 |
1 080 |
1 380 |
|
1 227 |
R&D, bln rub |
|
|
760.7 |
903.1 |
945.2 |
945.2 |
1 072 |
|
1 084 |
Interest expenses, bln rub |
|
|
15.8 |
18.4 |
16.3 |
19.2 |
17.6 |
|
0.000 |
|
Assets, bln rub |
|
|
7 237 |
8 503 |
8 293 |
8 293 |
9 363 |
|
12 971 |
Net Assets, bln rub |
? |
|
4 574 |
5 836 |
5 807 |
5 807 |
6 650 |
|
9 546 |
Debt, bln rub |
|
|
694.9 |
690.3 |
691.3 |
691.3 |
694.9 |
|
706.7 |
Cash, bln rub |
|
|
1 403 |
1 467 |
1 215 |
1 215 |
1 645 |
|
4 446 |
Net debt, bln rub |
|
|
-707.7 |
-776.5 |
-524.0 |
-524.0 |
-949.6 |
|
-3 739 |
|
Ordinary share price, rub |
|
|
91.2 |
129.6 |
74.6 |
74.6 |
76.3 |
|
65.5 |
Number of ordinary shares, mln |
|
|
622.6 |
623.3 |
619.0 |
619.0 |
606.7 |
|
597.2 |
|
Market cap, bln rub |
|
|
56 800 |
80 749 |
46 184 |
46 184 |
46 261 |
|
39 140 |
EV, bln rub |
? |
|
56 092 |
79 972 |
45 660 |
45 660 |
45 311 |
|
35 401 |
Book value, bln rub |
|
|
3 070 |
4 344 |
4 357 |
4 357 |
4 968 |
|
6 984 |
|
EPS, rub |
? |
|
1.32 |
2.41 |
2.46 |
2.46 |
2.31 |
|
6.96 |
FCF/share, rub |
|
|
1.04 |
2.25 |
0.00 |
1.54 |
1.04 |
|
1.26 |
BV/share, rub |
|
|
4.93 |
6.97 |
7.04 |
7.04 |
8.19 |
|
11.7 |
|
EBITDA margin, % |
? |
|
24.5% |
36.1% |
33.1% |
36.4% |
29.4% |
|
27.7% |
Net margin, % |
? |
|
18.8% |
28.7% |
28.3% |
28.3% |
23.4% |
|
72.6% |
FCF yield, % |
? |
|
1.14% |
1.74% |
0.00% |
2.06% |
1.36% |
|
1.92% |
ROE, % |
? |
|
18.0% |
25.8% |
26.2% |
26.2% |
21.1% |
|
43.5% |
ROA, % |
? |
|
11.4% |
17.7% |
18.4% |
18.4% |
15.0% |
|
32.0% |
|
P/E |
? |
|
69.0 |
53.7 |
30.3 |
30.3 |
33.0 |
|
9.42 |
P/FCF |
|
|
87.8 |
57.6 |
|
48.4 |
73.5 |
|
52.0 |
P/S |
? |
|
12.9 |
15.4 |
8.58 |
8.58 |
7.70 |
|
6.84 |
P/BV |
? |
|
18.5 |
18.6 |
10.6 |
10.6 |
9.31 |
|
5.60 |
EV/EBITDA |
? |
|
52.2 |
42.3 |
25.6 |
23.3 |
25.6 |
|
22.3 |
Debt/EBITDA |
|
|
-0.66 |
-0.41 |
-0.29 |
-0.27 |
-0.54 |
|
-2.36 |
|
R&D/CAPEX, % |
|
|
186.8% |
273.8% |
|
356.9% |
402.5% |
|
376.3% |
|
CAPEX/Revenue, % |
|
|
9.29% |
6.30% |
0.00% |
4.92% |
4.43% |
|
5.03% |
|
Edwards Lifesciences shareholders |